Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Clegg, Lindsay E., Heerspink, Hiddo J.L., Penland, Robert C., Tang, Weifeng, Boulton, David W., Bachina, Srinivas, Fox, Robert D., Fenici, Peter, Thuresson, Marcus, Mentz, Robert J., Hernandez, AdrianLanguage:
english
Journal:
Diabetes Care
DOI:
10.2337/dc18-1871
Date:
December, 2018
File:
PDF, 892 KB
english, 2018